Literature DB >> 30411703

Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study.

Meryem Demir1, Oğuzhan Deyneli2, Yusuf Yılmaz3.   

Abstract

BACKGROUND/AIMS: Non-alcoholic fatty liver disease is highly prevalent in patients with type 2 diabetes mellitus (T2DM). The aim of the present study was to investigate the potential usefulness of transient elastography (TE), which is a technique that allows measuring both fibrosis and liver fat content simultaneously, as a screening tool for hepatic involvement in Turkish patients with T2DM.
MATERIALS AND METHODS: We obtained liver stiffness measurements (LSMs, as a measure of fibrosis) and controlled attenuation parameter (CAP, as a marker of steatosis) in 124 (46 males and 78 females; mean body mass index (BMI): 33.2±6.6 kg/m2) Turkish patients with T2DM. The prevalence rates of overweight, obesity, and metabolic syndrome in our sample were 28.2%, 64.5%, and 77.4%, respectively. Probe-specific LSM cut-off values were used to define advanced fibrosis (>F3) and cirrhosis (F4) (M probe: F3=9.6-11.4 kPa, F4 >11.5 kPa and XL probe: F3=9.3-10.9 kPa, F4 >11.0 kPa). Mild, moderate, and severe steatosis were defined as CAP 222-232 dB/m, CAP 233-289 dB/m, and CAP >290 dB/m, respectively.
RESULTS: Advanced fibrosis and cirrhosis were identified in 21 (16.9%) and 10 (8.0%) patients, respectively. TE-defined hepatic steatosis (CAP>222 dB/m) was detected in 117 (94.3%) patients. Mild, moderate, and severe steatosis were identified in 0, 29, and 88 patients, respectively.
CONCLUSION: TE is a useful non-invasive imaging modality to screen for liver involvement in Turkish patients with T2DM. High rates of TE-defined fibrosis and steatosis in our sample reflect the presence of an elevated mean BMI.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30411703      PMCID: PMC6428511          DOI: 10.5152/tjg.2018.18559

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  22 in total

Review 1.  Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.

Authors:  Scott M Grundy; H Bryan Brewer; James I Cleeman; Sidney C Smith; Claude Lenfant
Journal:  Circulation       Date:  2004-01-27       Impact factor: 29.690

2.  Diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2014-01       Impact factor: 19.112

Review 3.  Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.

Authors:  Eugenia Tsai; Tai-Ping Lee
Journal:  Clin Liver Dis       Date:  2018-02       Impact factor: 6.126

Review 4.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.

Authors:  Parambir S Dulai; Siddharth Singh; Janki Patel; Meera Soni; Larry J Prokop; Zobair Younossi; Giada Sebastiani; Mattias Ekstedt; Hannes Hagstrom; Patrik Nasr; Per Stal; Vincent Wai-Sun Wong; Stergios Kechagias; Rolf Hultcrantz; Rohit Loomba
Journal:  Hepatology       Date:  2017-03-31       Impact factor: 17.425

5.  Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis.

Authors:  Yusuf Yilmaz; Yesim Ozen Alahdab; Oya Yonal; Ramazan Kurt; Alla Eldeen Kedrah; Cigdem Ataizi Celikel; Osman Ozdogan; Deniz Duman; Nese Imeryuz; Erol Avsar; Cem Kalayci
Journal:  Metabolism       Date:  2010-01-22       Impact factor: 8.694

6.  Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography.

Authors:  Yusuf Yilmaz; Rabia Ergelen; Hakan Akin; Nese Imeryuz
Journal:  Eur J Gastroenterol Hepatol       Date:  2013-11       Impact factor: 2.566

7.  Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis.

Authors:  Nicole E Rich; Stefany Oji; Arjmand R Mufti; Jeffrey D Browning; Neehar D Parikh; Mobolaji Odewole; Helen Mayo; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2017-09-29       Impact factor: 11.382

Review 8.  Diagnosis and evaluation of nonalcoholic fatty liver disease.

Authors:  Mikako Obika; Hirofumi Noguchi
Journal:  Exp Diabetes Res       Date:  2011-10-27

Review 9.  Alanine aminotransferase-old biomarker and new concept: a review.

Authors:  Zhengtao Liu; Shuping Que; Jing Xu; Tao Peng
Journal:  Int J Med Sci       Date:  2014-06-26       Impact factor: 3.738

10.  The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter.

Authors:  Young Eun Chon; Kwang Joon Kim; Kyu Sik Jung; Seung Up Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Chae Yoon Chon; Jae Bock Chung; Kyeong Hye Park; Ji Cheol Bae; Kwang Hyub Han
Journal:  Yonsei Med J       Date:  2016-07       Impact factor: 2.759

View more
  8 in total

Review 1.  Non-alcoholic fatty liver disease: A growing public health problem in Turkey.

Authors:  Eda Kaya; Yusuf Yılmaz
Journal:  Turk J Gastroenterol       Date:  2019-10       Impact factor: 1.852

2.  Prevalence of advanced liver fibrosis and steatosis in type-2 diabetics with normal transaminases: A prospective cohort study.

Authors:  Jasbir Makker; Hassan Tariq; Kishore Kumar; Madhavi Ravi; Danial Haris Shaikh; Vivien Leung; Umar Hayat; Muhammad T Hassan; Harish Patel; Suresh Nayudu; Sridhar Chilimuri
Journal:  World J Gastroenterol       Date:  2021-02-14       Impact factor: 5.742

3.  The utility of noninvasive scores in non-alcoholic fatty liver disease patients with normal and elevated serum transaminases.

Authors:  Eda Kaya; Alev Bakir; Fatih Eren; Yusuf Yilmaz
Journal:  Hepatol Forum       Date:  2020-01-20

4.  Simultaneously Screening for Liver Steatosis and Fibrosis in Romanian Type 2 Diabetes Mellitus Patients Using Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter.

Authors:  Anca Trifan; Ermina Stratina; Robert Nastasa; Adrian Rotaru; Remus Stafie; Sebastian Zenovia; Laura Huiban; Catalin Sfarti; Camelia Cojocariu; Tudor Cuciureanu; Cristina Muzica; Stefan Chiriac; Irina Girleanu; Ana-Maria Singeap; Carol Stanciu
Journal:  Diagnostics (Basel)       Date:  2022-07-20

5.  Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic.

Authors:  Ayşegül Avcu; Eda Kaya; Yusuf Yilmaz
Journal:  Turk J Gastroenterol       Date:  2021-05       Impact factor: 1.852

6.  The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade.

Authors:  Bülent Değertekin; Nurdan Tozun; Figen Demir; Gizem Söylemez; Şirin Parkan; Ezgi Gürtay; Deniz Mutlu; Meltem Toraman; Tolga Hayrettin Seymenoğlu
Journal:  Turk J Gastroenterol       Date:  2021-03       Impact factor: 1.852

7.  Screening for Liver Fibrosis and Steatosis in a Large Cohort of Patients with Type 2 Diabetes Using Vibration Controlled Transient Elastography and Controlled Attenuation Parameter in a Single-Center Real-Life Experience.

Authors:  Ioan Sporea; Ruxandra Mare; Alina Popescu; Silviu Nistorescu; Victor Baldea; Roxana Sirli; Adina Braha; Alexandra Sima; Romulus Timar; Raluca Lupusoru
Journal:  J Clin Med       Date:  2020-04-06       Impact factor: 4.241

8.  Correlation between Serum Ferritin Levels and Liver Stiffness measured by Fibroscan in patients with Chronic Hepatitis C.

Authors:  Saba Latif; Quratulain Kalam; Bader Faiyaz Zuberi
Journal:  Pak J Med Sci       Date:  2020 Mar-Apr       Impact factor: 1.088

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.